Johnson & Johnson
JNJ · Healthcare · Pharmaceuticals
Updated 27 min ago · data delayed ≥15 min
IconicScore
ProprietaryRanked #15 of 500 by Iconic Score · #2 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.
Get the free morning email
The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →
Price performance
Export history · AnalystThis insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.
Upgrade to AnalystThis is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.
Upgrade to EnterpriseIconic Profile
Johnson & Johnson (JNJ) is a leading global healthcare company with a market capitalization of $618.6 billion, primarily operating in the Pharmaceuticals sector. The company develops a wide range of products, including prescription medications, medical devices, and consumer health goods, with a strong emphasis on innovation and research. JNJ holds a prominent position in the market, benefiting from a diverse portfolio that addresses various health needs, including immunology, oncology, and infectious diseases. Its extensive distribution network and established brand reputation contribute to its competitive advantage. Johnson & Johnson's commitment to improving health outcomes and its ongoing investment in research and development underscore its significance in the healthcare landscape, making it a key player in addressing global health challenges.
IconicOracleAI™ Brief
Johnson & Johnson's Iconic Score of 74 reflects strong brand visibility, evidenced by a high logo analysis signal of 95/100. Recent discussions around the company's consistent dividend increases highlight its commitment to shareholders, despite trailing the S&P 500. Additionally, the market's focus on JNJ's drug portfolio and its impact on guidance contributes to ongoing attention, although the stock has experienced a slight decline of 0.61% today amid broader market movements.
AI-generated explanation of current score drivers. Not investment advice.
Enterprise tier: claim your logo to manage how your brand is represented.